Amneal Receives USFDA approval for Brekiya injection for the Acute Treatment of Migraine and Cluster Headaches in Adults
Amneal Pharmaceuticals, Inc. announced that the U.S. Food and Drug Administration has approved Brekiya dihydroergotamine mesylate injection, the first and only dihydroergotamine autoinjector for the acute treatment of migraine with or without aura and the acute treatment of cluster headaches in adults.